Midkine is a pleiotropic factor, which is involved in angiogenesis. However, its mode of action in this process is still ill defined. The function of midkine in arteriogenesis, the growth of natural bypasses from pre-existing collateral arteries, compensating for the loss of an occluded artery has never been investigated. Arteriogenesis is an inflammatory process, which relies on the proliferation of endothelial cells and smooth muscle cells. We show that midkine deficiency strikingly interferes with the proliferation of endothelial cells in arteriogenesis, thereby interfering with the process of collateral artery growth. We identified midkine to be responsible for increased plasma levels of vascular endothelial growth factor A (VEGFA), necessary and sufficient to promote endothelial cell proliferation in growing collaterals. Mechanistically, we demonstrate that leukocyte domiciled midkine mediates increased plasma levels of VEGFA relevant for upregulation of endothelial nitric oxide synthase 1 and 3, necessary for proper endothelial cell proliferation, and that non-leukocyte domiciled midkine additionally improves vasodilation. The data provided on the role of midkine in endothelial proliferation are likely to be relevant for both, the process of arteriogenesis and angiogenesis. Moreover, our data might help to estimate the therapeutic effect of clinically applied VEGFA in patients with vascular occlusive diseases.
Introduction
Vascular occlusive disease such as myocardial infarction, stroke or peripheral artery diseases are still a major cause of morbidity and mortality worldwide. Searching for new, non-invasive options to treat affected patients, much effort is made to understand the molecular mechanisms of arteriogenesis. Arteriogenesis is a tissue-and even lifesaving process and presents the growth of pre-existing collateral arterioles to natural biological bypasses. It is provoked by increased fluid shear stress and is mediated by sterile inflammation (Chillo et al., 2016) .
Midkine (MK) is a retinoic acid inducible cytokine, which is highly expressed during embryogenesis (Kadomatsu et al., 1990) . In the adulthood its expression is restricted to certain tissues but strongly induced during inflammatory processes (Badila et al., 2015) such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis (for an overview see (Weckbach et al., 2011) ), which are associated with angiogenesis. MK has also been implicated in angiogenesis and hence endothelial cell (EC) proliferation under conditions of tissue ischemia (Weckbach et al., 2012) and tumor growth (Choudhuri et al., 1997; Muramaki et al., 2003) as well as in neointima formation (Hayashi et al., 2005; Horiba et al., 2000) . The functional role of MK in angiogenesis is still not well defined, however, it was shown that MK induces chemotaxis of neutrophils and supports neutrophil adhesion during inflammation (Takada et al., 1997; Weckbach et al., 2014) . Neutrophils themselves express high levels of MK, but do not release it (Weckbach et al., 2012; Weckbach et al., 2014; Narita et al., 2008) . However, after stimulation with the chemokine (C-X-C) ligand 1 (CXCL1) neutrophils release angiogenic growth factor such as vascular endothelial growth factor A (VEGFA) (Scapini et al., 2004) .
The functional role of MK in arteriogenesis has never been investigated. Moreover, the functional role of VEGFA in arteriogenesis is controversially discussed (Jazwa et al., 2016) . In vitro data from Tzima et al., who EBioMedicine 27 (2018) [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] identified the VEGF receptor 2 (VEGFR-2), to be part of a mechanosensory complex and to be relevant for phosphoinositide 3-kinase (PI3K) activation, even suggested that VEGFR-2 is ligandindependent activated in response to shear stress (Tzima et al., 2005) . Here, we demonstrate that leukocyte domiciled midkine controls the plasma bioavailability of VEGFA, which in turn is relevant for the expression of neuronal nitric oxide synthase (Nos1) and endothelial Nos (Nos3) (but not inducible Nos (Nos2)) in endothelial cells of collaterals. For arteriogenesis all three isoform of NOS, namely NOS1, NOS2 and NOS3 are described to be involved, although the function of the individual NOS is not well defined (Troidl et al., 2010; Pagel et al., 2011) . Exclusively for NOS3 it has been shown that it mediates vasodilation in growing collaterals (Troidl et al., 2010) . Here we show that Nos1 or Nos3 expression, respectively, is essential for collateral endothelial cell proliferation, whereby both isoforms are likely to be able to substitute for each other.
Collectively, our data provide mechanistic insights into MKmediated endothelial cell proliferation, which are likely to be relevant not only for the process of arteriogenesis, but also for other inflammatory processes as well as tumor growth being associated with angiogenesis and hence endothelial cell proliferation.
Materials and Methods

Animals and Treatments
All experiments were carried out according to the German animal legislation guidelines and were approved by the Bavarian Animal Care and Use Committee. Mice were kept under a 12-hour (h) day and night cycle with chow and water provided ad libitum.
Mice were treated with either 100 μl DETA NONOate (Cayman Chemical, Ann Arbor, MI) 0.12 mg/ml intraperitoneal once daily in 0.9% NaCl (saline) (Braun, Melsungen, Germany), with 50 μl recombinant murine midkine (rmMK) (PeproTech, Rocky Hill, NJ) 0.1 mg/ml subcutaneously twice daily in saline or with 100 μl recombinant murine VEGFA164 (rmVEGFA) (Sigma-Aldrich, St. Louis, MO) 0.01 mg/ml intraperitoneal once daily in saline. Control groups received saline only. Sodium nitrite (Sigma-Aldrich) was applied via drinking water at a concentration of 1 g/l (Kumar et al., 2008; Hannas et al., 2010) . Control groups received normal drinking water. Treatment was started 3 days (d) before the surgical procedure and continued until the end of the experiments.
Femoral Artery Ligation, Laser Doppler Imaging and Bone Marrow Transplantation
Collateral artery growth was investigated in a murine hindlimb model (Chillo et al., 2016 ) using 8-to 10-week-old male Mdk −/− (carrying the Mdk tm1Tmu allele, RRID: MGI:3579532) (Nakamura et al., 1998) ,
/J, RRID: IMSR_JAX:002986) (Huang et al., 1993) mice and appropriate WT controls (C57BL/6J mice, RRID: IMSR_JAX:000664; Charles River, Sulzfeld, Germany). Mice underwent ligation of the right femoral artery distally to the origin of the profunda femoris branch using a 7-0 silk braided suture (Peasalls Sutures, Somerset, Great Britain). During the surgical procedures mice were under general anesthesia with a combination of fentanyl (0.05 mg/kg body weight) (Janssen-Cilag, Neuss, Germany), midazolam (5.0 mg/kg body weight) (Ratiopharm, Ulm, Germany) and medetomidine (0.5 mg/kg body weight) (Pfizer, New York, NY), which was administered subcutaneously. The left leg underwent sham operation and was used as control. Perfusion of the paws was assessed using a LDI technique (Moor LDI 5061 and Moor Software Version 3.01, Moor Instruments, Remagen, Germany) under temperature-controlled conditions. The measurements were conducted before FAL (basal), immediately after FAL (aFAL), 3d and 7d after FAL. Color-coded images of the paws representing the flux value were used to calculate the ratio of the tissue perfusion of the oc- 
Tissue and Blood Sampling
Heparinized blood gained by cardiac puncture was centrifuged (2.300g at 4°C for 20 min) and plasma was stored at −80°C. Prior to harvesting superficial collateral arteries for qRT-PCR (quantitative real-time PCR), both hind limbs were perfused with latex flexible compound (Chicago Latex, Chicago, IL) via a catheter in the abdominal aorta. For each mouse two superficial collateral arteries per side were isolated, snap frozen in dry ice and stored at −80°C until further investigations.
For histological analysis of collateral arteries, mice were perfused with 20 ml adenosine buffer (1% adenosine (Sigma-Aldrich), 5% bovine serum albumin (BSA, Sigma-Aldrich) dissolved in phosphate buffered saline (PBS, PAN Biotech, Aidenbach, Germany), pH 7.4), to assure maximum vasodilatation (Chillo et al., 2016) , followed by 20 ml 4% paraformaldehyde (PFA, Merck, Darmstadt, Germany) (for paraffin embedding) or 20 ml 3% PFA (for cryopreservation) in PBS, pH 7.4.
For histological analysis adductor muscles were rinsed in 4%PFA for 24 h and after paraffin embedding cut in 4 μm cross-sections. For immunofluorescence staining the samples were placed in 15% sucrose (Sigma-Aldrich), dissolved in PBS, for 4 h, followed by 30% sucrose, dissolved in PBS, overnight at 4°C. Afterwards the adductor muscle tissue was cryopreserved in tissue tek (Sakura, Alphen aan den Rijn, The Netherlands) and cut in 6 μm cross-sections.
Histology and Immuno-Histology
Paraffin embedded cross-sections were stained with GIEMSA according to standard procedures. VEGFA164 antibody (Cat#: AF-493-SP, RRID: AB_354506, Novus Biological, Littleton, CO, dilution 1:50, for 12 h at 4°C), secondary donkey anti-rabbit antibody (Cat#: A10040, RRID: AB_2534016, Thermo Fischer Scientific, dilution 1:200, for 1 h at room temperature), anti-Ly-6G antibody (Cat#: ab25024, RRID: AB_470400, Abcam, Cambridge, MA, dilution 1:100, for 12 h at 4°C) and DAPI (Cat#: D1306, RRID: AB_2629482, Thermo Fischer Scientific, dilution 1:1000, for 20 min at room temperature). Cross-sections were covered with Mowiol (Sigma-Aldrich) and analyzed with a confocal microscope (Leica SP5, Leica, Wetzlar Germany).
Protein Levels of VEGFA and MK
The VEGFA plasma level was measured with a standardized ELISA Kit (R&D Systems, Minneapolis, MN) following the manufacturer's protocol. The ready-SET-go Midkine ELISA-Kit (USCN Life Science Inc., Wuhan, China) was used to measure the MK plasma level following the manufacturer's protocol.
RNA Isolation, cDNA Synthesis and qRT-PCR
After isolating RNA from collateral arteries or primary endothelial cells with Trizol (Life technologies, Carlsbad, CA), RQ1 RNase-Free DNase (Promega, Madison, WI) digestion was used to remove residual genomic DNA. 250 ng purified RNA (using RNeasy MinElute columns (Qiagen, Hilden, Germany)) was reverse transcribed into cDNA with the QuantiTect Rev. Transcription Kit (Qiagen). For qRT-PCR analysis the SYBR Power Green Kit (Life Technologies) was used according to the manufacturer's protocol with 1 μl of the 1:5 diluted cDNA and 0.5 μM of each primer per reaction. For further information see the Supplemental Experimental Procedures.
Cell Culture
Mouse aortic ECs and SMCs were isolated as previously described (Kobayashi et al., 2005) . In brief, isolated murine aortas were filled with collagenase type II (Biochrom AG, Berlin, Germany) solution (2 mg/ml, dissolved in serum-free Dulbecco's Modified Eagle's Medium (DMEM, Sigma-Aldrich)) for 45 min at 37°C, and afterwards the ECs were flushed out of the aortas with DMEM containing 20% fetal calf serum (FCS, PAN Biotech). ECs were cultured with Complete Mouse Endothelial Cell Medium (Cellbiologics, Chicago, IL) on collagen A (Biochrom AG) coated flasks. The remaining aorta was cut into 2 mm pieces and placed on a 1% gelatin-coated dish (PAN Biotech). gelatine coated flasks. Medium was changed every other day and passages 1 to 3 were used for experiments.
In Vitro BrdU Proliferation Assays
A 96-well plate with 1.2 × 10 4 ECs or SMCs per well and a standardized BrdU proliferation kit (Roche, Basel, Switzerland) was used to analyze the in vitro proliferation of isolated ECs or SMCs. For further information see the Supplemental Experimental Procedures.
Statistical Analysis
Experimenters were blind to outcome assessment for all experiments. All statistical analysis were performed with GraphPad software PRISM6 (GraphPad Software, La Jolla, CA) and are specified in the Figure legends. Data shown are means ± SD. Results were considered to be statistically significant at P b 0.05.
Results
Midkine Is Essential for EC Proliferation of Growing Collateral Arteries
To characterize the functional role of MK in arteriogenesis, we investigated a murine hindlimb model in which femoral artery ligation (FAL, Occ) results in collateral artery growth (Chillo et al., 2016) . Our data showed that FAL results in a reduced increase in caliber size and tortuosity of superficial collateral arteries as well as a significantly reduced perfusion recovery in Mdk deficient (Mdk −/− ) compared to wild-type (WT) mice (Fig. 1a-c) . To investigate whether the reduced perfusion recovery observed in Mdk −/− mice was due to a reduced number of pre- significantly smaller increase in luminal diameter after FAL (Fig. 2a and  b) . Moreover, the ratio of the vessel wall thickness to the luminal diameter was significantly increased in Mdk −/− mice (Fig. 2c) . BrdU staining revealed a significantly decreased percentage of proliferating ECs in Mdk −/− mice, whereas there was no significant difference in the number of proliferating smooth muscle cells (SMCs) (Fig. 2d and e) .
Leukocyte Domiciled MK Promotes Collateral Artery Growth
MK plasma levels prior to any surgical procedure (basal), 12 h and 24 h after FAL were below the detection range. At 3d after FAL, MK plasma level increased to 0.268 ± 0.012 ng/ml and decreased again at 7d (Fig. 3a) . The Mdk mRNA expression levels significantly increased in collaterals 12 h and 24 h after FAL (Fig. 3b) . Immunofluorescence double staining against MK and Ly-6G performed on tissue samples isolated 24 h after FAL evidenced that MK is present in perivascular neutrophils (Fig. 3c) (Fig. 3f) .
Rescue of Arteriogenesis in Mdk −/− Mice
In order to elucidate the function of exogenous MK on the growth of collaterals, mice were treated with recombinant murine MK (rmMK). Treatment with rmMK normalized perfusion recovery, the luminal diameter, the ratio of the vascular wall to the luminal diameter and EC proliferation in Mdk −/− mice, but did not influence SMC proliferation (Fig. 4a and c-f) . WT mice treated with rmMK showed significantly increased perfusion recovery 7d after FAL compared to saline treated WT mice, but the proliferation rate of vascular cells and the growth of collateral arteries were unchanged (Fig. 4a and c-f) . Thus exogenous MK improved perfusion recovery in Mdk −/− mice via collateral growth, whereas increased perfusion recovery in WT mice was due to vasodilatation. This data suggested that MK not only promotes collateral growth, but also regulates the expression of Nos responsible for vasodilation. Accordingly, Mdk −/− and WT mice were treated with the NO-donor DETA NONOate. In Mdk −/− mice DETA NONOate treatment significantly increased perfusion recovery and normalized EC proliferation and collateral artery growth, whereas SMC proliferation was unaffected ( Fig. 4b-f ). In WT mice perfusion recovery, collateral growth as well as vascular cell proliferation was unchanged by DETA NONOate treatment ( Fig. 4b-f) . qRT-PCR analysis on collaterals isolated 12 h after FAL evidenced significantly decreased Nos1 and Nos3 expression levels in Mdk −/− mice compared to WT mice, while Nos2 expression levels showed no significant differences (Fig. 4g ). Since it is well described that Nos3 deficiency is not associated with reduced collateral artery growth (Troidl et al., 2010; Mees et al., 2007) , but that NOS3 is relevant for proper vasodilation during arteriogenesis (Troidl et al., 2010) , we asked about the relevance of Nos1 for arteriogenesis. Nos1 −/− mice did not show a reduced perfusion recovery after FAL. However, in contrast to WT and Mdk −/− mice, NO-donor treatment strikingly interfered with perfusion recovery in Nos1 −/− mice (Fig. S4) .
Inhibition of NOS Blocks the Proliferative Effect of rmMK on ECs In Vitro
Primary ECs of Mdk −/− showed significantly reduced basal expression levels of Nos1 and Nos3 (Fig. 5a ) as well as a significantly reduced proliferation rate (Fig. 5b) in DMEM medium alone (Control), or with the specific VEGFR-2 inhibitor SU1498 (100 ng/ml), with rmVEGFA (50 ng/ml), or a combination of SU1498 and rmVEGFA. Values for WT cells cultured with 2%FCS in DMEM alone (Control) were defined as 100%. n = 5. *P b 0.05 two-way ANOVA with Bonferroni's multiple comparison test. Data are means ± SD.
Relationship Between MK and VEGFA
Since NO has been described to induce the expression of VEGFA and vice versa (Kroll and Waltenberger, 1998; Kimura and Esumi, 2003 ), we investigated the plasma level of VEGFA of WT and Mdk −/− mice. Prior to any surgical procedure (basal), the plasma level of VEGFA was comparable in WT and Mdk −/− mice (Fig. 6a) . 24 h after FAL the VEGFA plasma level increased significantly in WT mice, but not in Mdk −/− mice. Treatment with rmMK normalized the VEGFA plasma level of Mdk −/− mice, but showed no effect on the plasma level of WT mice. DETA NONOate treatment in contrast did not influence the plasma level of VEGFA either in WT or Mdk −/− mice. Immunohistological analysis identified neutrophils as potential source VEGFA (Fig. 6b) . 7d after FAL, treatment with rmVEGFA significantly increased perfusion recovery and luminal diameter of Mdk −/− mice, however, showed no effect on WT mice ( Fig. 6c and d) . Moreover, treatment with rmVEGFA normalized Nos1 and Nos3 expression levels in collaterals of Mdk −/− mice, whereas Nos2 expression levels were not affected either in WT or Mdk −/− mice (Fig. 6e) .
Accompanying in vitro results evidenced that inhibition of VEGFR-2 by SU1498 significantly reduced the proliferation rate of primary WT ECs, but not of primary Mdk −/− ECs (Fig. 6f ). Although having a broader specificity, SU1498 has been used in many experiments to block VEGFR-2 (e.g. (Greenberg and Jin, 2013) ). Treatment with rmVEGFA in contrast significantly increased the proliferation rate of primary WT ECs and primary Mdk −/− ECs.
Discussion
In this study we identified MK as factor relevant for proper collateral EC proliferation during arteriogenesis. Our data indicate that MK regulates the bioavailability of VEGFA and modulates the differential expression of Nos1 and Nos3 in vascular ECs. A proposed model for the action of MK is shown in Fig. 7 .
Femoral artery ligation resulted in the growth of an identical number of collateral arteries in WT and Mdk −/− mice. However, the collaterals of Mdk −/− mice showed a reduced increase of the luminal diameter with an increase of the ratio of vascular wall to luminal diameter. Thus, perfusion recovery in Mdk −/− mice was impaired due to diminished outward remodeling, although limited vasodilatation might also have contributed (see below). This kind of hypertrophic outward remodeling occurs whenever EC proliferation (intima proliferation) is compromised, while the proliferation of the media and adventitia layer is not affected (Mulvany, 1999) . Indeed, our BrdU staining revealed a reduced proliferation of collateral ECs in Mdk −/− mice, while the proliferation of SMC was not negatively affected. Together, these data identify MK as cytokine relevant for collateral EC proliferation and confirm the importance of EC proliferation for the process of arteriogenesis (Moraes et al., 2013) . The initial phase of collateral growth relies on extravasation of leukocytes, especially neutrophils (Chillo et al., 2016) . Our immunohistochemical analyses together with our bone marrow transplantation experiments identified neutrophil-domiciled midkine as relevant for arteriogenesis while non-bone marrow cell derived MK influenced perfusion recovery by increased vasodilatation. Although our data evidenced that MK is not released from leukocytes, thereby confirming previous results (Weckbach et al., 2012) , we found increased plasma levels of MK 3d and 7d after FAL. FAL results -due to increased shear stress -in arteriogenesis in the upper leg, and timely delayed -due to ischemia in angiogenesis in the lower leg (Ito et al., 1997) . Hypoxic ECs were recently identified as source of soluble MK in the vascular system (Weckbach et al., 2012) . Accordingly it is likely that the MK observed in plasma derived from hypoxic ECs from the lower leg.
Treatment (Weckbach et al., 2011) , however, it has been shown in human umbilical vein endothelial cells (HUVECs) that stimulation with MK resulted in binding and phosphorylation of anaplastic lymphoma kinase (ALK, the receptor for PTN (pleiotrophin)) and activation of PI3K (Stoica et al., 2002) . There is ample of evidence relating PI3K to Nos1 expression (Fujibayashi et al., 2015) as well as to NOS1 (Wu et al., 2016) and NOS3 (Fisslthaler et al., 2000) activation. Together, these data suggest that ALK might have mediated the vasodilatory function of rmMK in WT mice (see also Fig. 7 ). However, it might be interesting to mention that intracellular MK is also capable to activate pI3K (Khan et al., 2017) . NO, particularly derived from NOS3 has been described to promote EC proliferation in vitro and angiogenesis in vivo (Fukumura et al., 2001; Cai et al., 2006; Lee et al., 1999) . But studies on Nos3 −/− mice suggested that NOS3 is not essential for arteriogenesis, and reduced perfusion recovery was attributed to reduced vasodilation (Troidl et al., 2010; Mees et al., 2007) . Nos1 has previously been described to be upregulated during arteriogenesis, however, its functional role remains to be elucidated (Pagel et al., 2011) . Our current study showed that reperfusion recovery is not reduced in Nos1 −/− mice. However, in contrast to WT or Mdk −/− mice, in which treatment with an NO-donor either did not affect (WT mice) or even promoted (Mdk −/− mice) arteriogenesis, it showed deleterious effects on perfusion recovery in Nos1 −/− mice indicating that the loss of NOS1 was compensated in a manner not tolerating increased levels of NO. Whereas NOS2 and NOS3 are mainly described to be involved in NO production, NOS1 has been more implicated in H 2 O 2 generation (Capettini et al., 2010; Costa et al., 2016) . However, also NOS3 can generate H 2 O 2 when uncoupled (Li et al., 2002) . Interestingly, NO (Cai et al., 2006) as well as H 2 O 2 (Oshikawa et al., 2010; Li et al., 2015) have been shown to play a role in EC proliferation, and both NOS isoforms are described to be capable to substitute for each other (Son et al., 1996) . For example it has been show in a rodent model of cerebral aneurisma (CA) formation that expression of Nos1 (but not Nos2) was upregulated in Nos3 −/− mice (Aoki et al., 2011) . Moreover, the incidence of CA formation was neither affected in Nos1 nor Nos3 deficient mice, however, increased in mice deficient for both genes (Aoki et al., 2011) . We have previously shown that VEGFA is not differentially expressed in the muscle tissue surrounding growing collaterals and is not at all expressed in collaterals (Deindl et al., 2001) . Hence it was likely that the increased plasma levels of VEGFA detected 24 h after induction of arteriogenesis derived from a different source. Our immunohistological results evidenced that VEGFA is present in neutrophils. Interestingly, we have recently found that neutrophils are recruited to growing collaterals at the time point we now observed increased plasma levels of VEGFA (Chillo et al., 2016) . A study on mesenchymal stem cells revealed that overexpression of MK resulted in increased mRNA expression levels of Vegfa, as well as increased amounts of VEGFA in cell supernatant (Zhao et al., 2014) . Accordingly, our results suggest that expression of VEGFA in neutrophils was responsible for increased plasma levels of VEGFA in rmMK treated Mdk −/− mice, but also in WT mice showing MK expression in neutrophils. Neutrophils are well described to play an important role in angiogenesis by supplying growth factors such as VEGFA (Gong and Koh, 2010; Scapini et al., 2004) . Moreover, it has been demonstrated in a femoral artery ligation model that angiogenesis occurring in ischemic tissue is dependent on VEGFA released from neutrophils (Ohki et al., 2005) . We have recently shown that angiogenesis is severely compromised in ischemic muscles of Mdk −/− mice after femoral artery ligation (Weckbach et al., 2012) . Together, these data suggest that MK is relevant for the bioavailability of neutrophil-derived VEGFA not only in arteriogenesis, but also in angiogenesis. It has been shown very elegantly by Scapini in vivo (Scapini et al., 2004 ) that neutrophil-derived VEGFA dependent angiogenesis is mediated by CXCL-1. Moreover, it has been demonstrated by several studies that blocking the CXCL-1 receptor CXCR2 interferes with angiogenesis (e.g. (Sukkar et al., 2008) ). Platelets, of which we have shown to play an important role in arteriogenesis by activating neutrophils (Chandraratne et al., 2015; Chillo et al., 2016) are a rich source of CXCL-1. However, CXCL1, is also upregulated in ECs due to shear stress in vitro (Hagiwara et al., 1998) and in growing collaterals in vivo (Vries et al., 2015) . Indeed it was recently demonstrated that blocking the CXCL-1 receptor CXCR2 interferes with arteriogenesis (Vries et al., 2015) . Together these data suggest that CXCL-1 induced expression and release of VEGFA from neutrophils is mediated by MK. A proposed model for arteriogenesis is shown in Fig. 7 .
Although not investigated in the present study, it is likely that at later time points of arteriogenesis (d3 and d7), where monocytes play a role (Troidl et al., 2013) , VEGFA is supplied by this type of leukocyte, since also monocytes are a source of both, MK (Badila et al., 2015) and VEGFA (Ramanathan et al., 2003) .
In our study, administration of rmVEGFA rescued arteriogenesis in Mdk −/− mice substantiating the relationship between MK and VEGFA.
Administration of rmVEGFA to WT mice in contrast showed no effect on arteriogenesis confirming previous results (Jazwa et al., 2016) . Together these data suggest that MK mediated increased bioavailability of VEGFA is necessary and sufficient to promote arteriogenesis under normal physiological conditions by regulating the expression level of Nos1 and Nos3 via activation of VEGFR-2. Increasing the current number of mice per group (n = 5 or n = 4) should strengthen the data in future studies. In summary, we provide evidence that NO synthase, in particular NOS1 and NOS3 isoforms are decisive for EC proliferation in arteriogenesis. Moreover, we show that the expression of these NO synthases is mediated by MK by increasing the bioavailability of VEGFA. Together, these results might have profound impact on the treatment of patients with vascular occlusive diseases. 
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